CDA | Evidence Driven
CDA | Evidence Driven

Proleukin for In-transit Melanoma - Details

Détails

Fichiers
Generic Name:
Aldesleukin (IL-2)
État du projet:
Terminé
Domaine thérapeutique:
In-transit Melanoma
Fabricant:
Novartis Pharmaceuticals Canada Inc.
Brand Name:
Proleukin
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0051-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
22 million IU/vial
Tumour Type:
Peau et mélanome
Indications:
In-transit Melanoma
Funding Request:
Administered intra-lesionally, for the treatment of in-transit metastasis from melanoma in patients who have failed or are not candidates for surgery or other treatments
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Cancer Care Ontario Melanoma Disease Site Group
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Couvrir le remboursement
pERC Meeting:
Final Recommendation Issued:

Fichiers

Provincial Funding Summary Résumé, financement provincial Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma - Final pERC Recommendation Recommandation finale 22 juin 2015 Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Final Clinical Guidance Report Rapports d'orientation 22 juin 2015 Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Final Economic Guidance Report Rapports d'orientation 22 juin 2015 Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Initial Recommendation Recommandation initiale 04 juin 2015 Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma - PAG Feedback on Initial Recommendation Rétroaction 22 juin 2015 Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Submitter Feedback on Initial recommendation Rétroaction 22 juin 2015 Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Patient Advocacy Group (MNC) Feedback on Initial Recommendation Rétroaction 22 juin 2015 Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Patient Advocacy Group (MNC) COI Déclarations de conflit d’intérêts 22 juin 2015 Afficher le PDF
Aldesleukin (IL-2) (Proleukin) In-transit Melanoma – Patient Advocacy Group (SYSF) COI Déclarations de conflit d’intérêts 22 juin 2015 Afficher le PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Dernière mise à jour : 02 septembre 2016